Twenty-two adult ALL patients (21/22 in complete remission [CR]) received reduced intensity conditioning (RIC) followed by allogeneic transplantation. All patients were high risk. Following a uniform preparative regimen (fludarabine 40 mg/m2 x 5, cyclophosphamide 50 mg/kg, 200 cGy total body irradiation) patients received either matched related (n=4) or umbilical cord (n=18) donor grafts. All patients reached neutrophil engraftment and 100% donor chimerism (median days 10 and 23). Overall survival, treatment related mortality and relapse were 50% (95% CI: 27-73%), 27% (95% CI: 9-45%), 36% (95% CI: 14-58%) at 3 years, respectively. There were no relapses beyond 2 years. The cumulative incidence of acute and chronic graft versus host disease was 55% and 45%. HCT in CR1 (n=14) led to significantly less TRM (8%, p<0.04) and improved OS (81%, p<0.01). For adults with ALL in CR, RIC allografting results in modest TRM, limited risk of relapse and promising leukemia-free survival.
INTRODUCTION
In contrast to 80% disease-free survival for children with acute lymphoblastic leukemia (ALL), the adults fare much worse; only a third survive beyond 5 years. 1, 2 Older adults with ALL are frequently high risk (Ph + chromosome or high white blood count) yielding a poor prognosis. 3 The >85% relapse rate in patients with Ph + ALL was reduced by donor hematopoietic cell transplantation (HCT), implying that a graft-versus leukemia (GVL) effect may cure ALL. 3, 4, 5 Recently, a landmark publication from MRC/ECOG reported the outcomes of >1900 adult ALL patients in first complete remission (CR1) and showed improved survival (~53%) for patients allocated to sibling HCT versus either consolidation/maintenance chemotherapy or autologous HCT. 7 The best survival was observed in standard risk ALL patients < 35 years. The benefit for older patients was abrogated by unacceptably high treatment related mortality (TRM). 7, 8 The optimal therapy for older patients or those unable to tolerate myeloablative conditioning is uncertain. Allogeneic HCT using reduced intensity conditioning (RIC) has promise for limiting TRM while its anti-leukemia potency is uncertain. 9-11 We present results of 22 patients with high risk ALL in CR undergoing RIC allotransplantation and show modest TRM and promising leukemia-free survival.
METHODS AND PATIENTS
We analyzed data from 22 consecutive patients with ALL enrolled on allogeneic RIC HCT studies which were prospectively collected in the University of Minnesota Blood 
TREATMENT PLAN
The transplant protocol was approved by the University of Minnesota Institutional 
STATISTICAL ANALYSIS
Kaplan-Meier estimates of overall survival (OS) and cumulative incidence (CI) estimates of TRM, engraftment, GVHD, and relapse were calculated as of June 2008. 13, 14 Log-rank statistics were used to compare time to event curves. Event times were measured from the date of transplantation to the date of death or last contact.
RESULTS AND DISCUSSION
All patients had sustained neutrophil engraftment (>0.5 x 10 9 /L) at median 10 days (range 0-28) and 77% (95% CI, 54-100%) had an unsupported platelet count above 20 x 10 9 /L at a median of 38 days after transplant (range 0-167). All patients achieved 100% donor chimerism at a median 23 days post-transplant (range 14-99).
At three years, OS was 50% (95% CI, 27-73%; Figure 1A ). For 12 patients in CR1, three year OS was 81% (95% CI, 57-100%) compared to 15% (95% CI, 0-40%) for patients transplanted in ≥ CR2 (p<0.01). TRM at three years was 27% (95% CI, 9-45%; Figure   1B ) with no events after 6 months. At day 100 the cumulative incidence of Grade II-IV and III-IV acute GVHD were 55%
(95% CI, 32 -88%) and 20% (95% CI, 3-37%), respectively. One year survival of patients with Grade II-IV acute GVHD was significantly improved (RR=0.2 (95% CI, 0.05-0.8; P= 0.02). One year cumulative incidence of chronic GVHD was 45% (95% CI, 21-69%), seven were extensive.
While the MRC-ECOG and CIBMTR reports of myeloablative allografts for adult ALL in CR1 demonstrate OS of 40-53%, patients older than 35 years had substantially worse TRM and survival. 3, 7, 16 Our data suggest that survival can be improved using RIC HCT.
RIC allograft for adult ALL may limit TRM, particularly if performed in CR1. Rapid, complete donor engraftment was achieved without donor lymphocyte infusion. Most of our patients received UCB grafts and their outcomes suggest that UCB is a valuable option for older patients with ALL who lack a matched or sufficiently healthy sibling 2, 6 suggests that the prevention of relapse with allografting in CR1 is the best opportunity to achieve long-term survival. RIC HCT may be particularly relevant for Ph + ALL. The widespread use of TKIs during induction chemotherapy can limit minimal residual leukemia 17, 18 and favorably influence subsequent outcome if RIC regimens are used. While earlier reports suggest feasibility and reduced TRM of RIC allotransplantation for adult ALL, many enrolled patients had advanced persistent or refractory ALL (40% in EMBT registry analysis) 11 leading to poor leukemia control and relapse rates of 49-60%. Our data show that OS for ALL patients following RIC HCT is comparable to that achieved with conventional allografting. 4, 11, [19] [20] [21] [22] Long term follow-up is warranted to confirm the rates of sustained and durable remissions. The results from this relatively small cohort are encouraging and justify enrolling patients in future trials testing RIC HCT for ALL patients in CR1 or later CR who are unsuited for more intensive, myeloablative conditioning.
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